Evidence map›Paper›PMID 37919672›Full record

ArticleBMC genomic data2023

3-D chromatin conformation, accessibility, and gene expression profiling of triple-negative breast cancer.

Pere Llinàs-Arias, Miquel Ensenyat-Méndez, Javier I J Orozco, Sandra Íñiguez-Muñoz, Betsy Valdez, Chuan Wang, Anja Mezger, Eunkyoung Choi, Yan Zhou Tran, Liqun Yao and 6 more

Abstract read
In one paragraph

Article in BMC genomic data, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Pere Llinàs-Arias *Cancer Epigenetics Laboratory at the Cancer Cell Biology Group, Health Research Institute of the Balearic Islands (IdISBa), 07120, Palma, Spain.
Miquel Ensenyat-Méndez *Cancer Epigenetics Laboratory at the Cancer Cell Biology Group, Health Research Institute of the Balearic Islands (IdISBa), 07120, Palma, Spain.
Javier I J OrozcoSaint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Sandra Íñiguez-MuñozCancer Epigenetics Laboratory at the Cancer Cell Biology Group, Health Research Institute of the Balearic Islands (IdISBa), 07120, Palma, Spain.
Betsy ValdezSaint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA.
Chuan WangDepartment of Biosciences and Nutrition, Science for Life Laboratory,, Karolinska Institutet, Stockholm, Sweden.
Anja MezgerScience for Life Laboratory, Division of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.
Eunkyoung ChoiScience for Life Laboratory, Division of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.
Yan Zhou TranDepartment of Biosciences and Nutrition, Science for Life Laboratory,, Karolinska Institutet, Stockholm, Sweden.
Liqun YaoDepartment of Biosciences and Nutrition, Science for Life Laboratory,, Karolinska Institutet, Stockholm, Sweden.
Franziska BonathDepartment of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Stockholm, Sweden.
Remi-André OlsenDepartment of Biochemistry and Biophysics, Science for Life Laboratory, Stockholm University, Stockholm, Sweden.
Mattias OrmestadScience for Life Laboratory, Division of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.
Manel EstellerJosep Carreras Leukaemia Research Institute, Badalona, Barcelona, Catalonia, Spain.
Mathieu LupienPrincess Margaret Cancer Centre, Toronto, Toronto, ON, M5G 1L7, Canada.
Diego M MarzeseCancer Epigenetics Laboratory at the Cancer Cell Biology Group, Health Research Institute of the Balearic Islands (IdISBa), 07120, Palma, Spain. diego.marzese@ssib.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTriple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Unlike other breast cancer subtypes, the scarcity of specific therapies and greater frequencies of distant metastases contribute to its aggressiveness. We aimed to find epigenetic changes that aid in the understanding of the dissemination process of these cancers. DATA DESCRIPTION: Using CRISPR/Cas9, our experimental approach led us to identify and disrupt an insulator element, IE8, whose activity seemed relevant for cell invasion. The experiments were performed in two well-established TNBC cellular models, the MDA-MB-231 and the MDA-MB-436. To gain insights into the underlying molecular mechanisms of TNBC invasion ability, we generated and characterized high-resolution chromatin interaction (Hi-C) and chromatin accessibility (ATAC-seq) maps in both cell models and complemented these datasets with gene expression profiling (RNA-seq) in MDA-MB-231, the cell line that showed more significant changes in chromatin accessibility. Altogether, our data provide a comprehensive resource for understanding the spatial organization of the genome in TNBC cells, which may contribute to accelerating the discovery of TNBC-specific alterations triggering advances for this devastating disease.

Indexed as

Triple Negative Breast NeoplasmsBreastCell Line, TumorChromatinGene Expression ProfilingHumansChromatinATAC-seqChromatin accessibilityEpigenetic profilingHi-CLong-range interactionsMDA-MB-231MDA-MB-436RNA levelsRNA-seq

Identifiers

PMID37919672
PMCPMC10621134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.